The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,295
Sort by:
The 2027-2032 World Outlook for Epilepsy Therapeutics
US$ 1,195.00
This study covers the world outlook for epilepsy therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.)...
January 2026
287 pages
The 2027-2032 World Outlook for Epinephrine Auto-Injectors
US$ 1,195.00
This study covers the world outlook for epinephrine auto-injectors across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P....
January 2026
287 pages
The 2027-2032 World Outlook for Epoetin-Alfa
US$ 1,195.00
This study covers the world outlook for epoetin-Alfa across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the...
January 2026
287 pages
The 2027-2032 World Outlook for Erythropoietin Drugs
US$ 1,195.00
This study covers the world outlook for erythropoietin drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Fabry Disease Treatments
US$ 1,195.00
This study covers the world outlook for Fabry disease treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I....
January 2026
287 pages
The 2027-2032 World Outlook for Flu Treatments
US$ 1,195.00
This study covers the world outlook for flu treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for t...
January 2026
287 pages
The 2027-2032 World Outlook for Foot Care Medicines
US$ 1,195.00
This study covers the world outlook for foot care medicines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Gastroparesis Drugs
US$ 1,195.00
This study covers the world outlook for gastroparesis drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Gaucher Disease Treatments
US$ 1,195.00
This study covers the world outlook for gaucher disease treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P....
January 2026
288 pages
The 2027-2032 World Outlook for Genital Herpes Treatments
US$ 1,195.00
This study covers the world outlook for genital herpes treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I...
January 2026
287 pages
The 2027-2032 World Outlook for Genitourinary Drugs
US$ 1,195.00
This study covers the world outlook for genitourinary drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Germcitabine HCI
US$ 1,195.00
This study covers the world outlook for germcitabine HCI across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
287 pages
The 2027-2032 World Outlook for Gonorrhea Therapeutics
US$ 1,195.00
This study covers the world outlook for gonorrhea therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E....
January 2026
287 pages
The 2027-2032 World Outlook for Gout Therapeutics
US$ 1,195.00
This study covers the world outlook for gout therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), fo...
January 2026
287 pages
The 2027-2032 World Outlook for Gynecology Drugs
US$ 1,195.00
This study covers the world outlook for gynecology drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
287 pages
The 2027-2032 World Outlook for Hemarrhoid Treatments
US$ 1,195.00
This study covers the world outlook for hemarrhoid treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.)...
January 2026
287 pages
The 2027-2032 World Outlook for Hemophilia a Drugs
US$ 1,195.00
This study covers the world outlook for hemophilia a drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), f...
January 2026
287 pages
The 2027-2032 World Outlook for Hemophilia a Treatments
US$ 1,195.00
This study covers the world outlook for hemophilia a treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E...
January 2026
287 pages
The 2027-2032 World Outlook for Hemophilia Drugs
US$ 1,195.00
This study covers the world outlook for hemophilia drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
287 pages
The 2027-2032 World Outlook for Hemophilia Treatments
US$ 1,195.00
This study covers the world outlook for hemophilia treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.)...
January 2026
287 pages
The 2027-2032 World Outlook for Heparin
US$ 1,195.00
This study covers the world outlook for heparin across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the coun...
January 2026
287 pages
The 2027-2032 World Outlook for Heparin Anticoagulants
US$ 1,195.00
This study covers the world outlook for heparin anticoagulants across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E....
January 2026
287 pages
The 2027-2032 World Outlook for Heparin Sodium
US$ 1,195.00
This study covers the world outlook for heparin sodium across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for t...
January 2026
287 pages
The 2027-2032 World Outlook for Hepatitis C Drugs
US$ 1,195.00
This study covers the world outlook for hepatitis c drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), fo...
January 2026
287 pages
The 2027-2032 World Outlook for Hepatitis C Therapeutics
US$ 1,195.00
This study covers the world outlook for hepatitis c therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I....
January 2026
287 pages
The 2027-2032 World Outlook for Hepatitis Therapeutics
US$ 1,195.00
This study covers the world outlook for hepatitis therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E....
January 2026
287 pages
The 2027-2032 World Outlook for Herbal Medicinal Products
US$ 1,195.00
This study covers the world outlook for herbal medicinal products across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I...
January 2026
288 pages
The 2027-2032 World Outlook for Herbal Medicines
US$ 1,195.00
This study covers the world outlook for herbal medicines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
288 pages
The 2027-2032 World Outlook for HIV-1 Therapeutics
US$ 1,195.00
This study covers the world outlook for HIV-1 therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), f...
January 2026
287 pages
The 2027-2032 World Outlook for HIV-AIDS Drugs
US$ 1,195.00
This study covers the world outlook for HIV-AIDS drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for t...
January 2026
287 pages
The 2027-2032 World Outlook for HIV Drugs
US$ 1,195.00
This study covers the world outlook for HIV drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the co...
January 2026
287 pages
The 2027-2032 World Outlook for HIV Therapeutics
US$ 1,195.00
This study covers the world outlook for HIV therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
287 pages
The 2027-2032 World Outlook for Homeopathic Products
US$ 1,195.00
This study covers the world outlook for homeopathic products across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Homeopathy Products
US$ 1,195.00
This study covers the world outlook for homeopathy products across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
